JW Shinyak Corporation (067290) - Total Liabilities

Latest as of September 2025: ₩26.02 Billion KRW ≈ $17.63 Million USD

Based on the latest financial reports, JW Shinyak Corporation (067290) has total liabilities worth ₩26.02 Billion KRW (≈ $17.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

JW Shinyak Corporation - Total Liabilities Trend (2007–2024)

This chart illustrates how JW Shinyak Corporation's total liabilities have evolved over time, based on quarterly financial data. See JW Shinyak Corporation working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

JW Shinyak Corporation Competitors by Total Liabilities

The table below lists competitors of JW Shinyak Corporation ranked by their total liabilities.

Company Country Total Liabilities
Drilling Tools International Corp.
NASDAQ:DTI
USA $104.27 Million
Applied BioCode
TW:6598
Taiwan NT$343.23 Million
Masisa
SN:MASISA
Chile CL$199.35 Million
Globrands Group Ltd
TA:GLRS
Israel ILA570.15 Million
Daesung Holdin
KO:016710
Korea ₩474.66 Billion
Asahimas Flat Glass Tbk
JK:AMFG
Indonesia Rp2.68 Trillion
ZK International Group Co Ltd
NASDAQ:ZKIN
USA $38.25 Million
Gain Therapeutics Inc
NASDAQ:GANX
USA $4.73 Million

Liability Composition Analysis (2007–2024)

This chart breaks down JW Shinyak Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JW Shinyak Corporation (067290) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.67 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.40 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JW Shinyak Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JW Shinyak Corporation (2007–2024)

The table below shows the annual total liabilities of JW Shinyak Corporation from 2007 to 2024.

Year Total Liabilities Change
2024-12-31 ₩36.14 Billion
≈ $24.49 Million
-26.52%
2023-12-31 ₩49.17 Billion
≈ $33.32 Million
+29.00%
2022-12-31 ₩38.12 Billion
≈ $25.83 Million
+4.27%
2021-12-31 ₩36.56 Billion
≈ $24.78 Million
-8.07%
2020-12-31 ₩39.77 Billion
≈ $26.95 Million
-43.76%
2019-12-31 ₩70.71 Billion
≈ $47.92 Million
-6.61%
2018-12-31 ₩75.72 Billion
≈ $51.31 Million
-12.49%
2017-12-31 ₩86.53 Billion
≈ $58.64 Million
-17.60%
2016-12-31 ₩105.01 Billion
≈ $71.16 Million
+20.08%
2015-12-31 ₩87.45 Billion
≈ $59.26 Million
+3.45%
2014-12-31 ₩84.53 Billion
≈ $57.29 Million
+3.88%
2013-12-31 ₩81.38 Billion
≈ $55.15 Million
+23.04%
2012-12-31 ₩66.14 Billion
≈ $44.82 Million
+32.31%
2011-12-31 ₩49.99 Billion
≈ $33.88 Million
+135.31%
2008-12-31 ₩21.24 Billion
≈ $14.40 Million
-0.58%
2007-12-31 ₩21.37 Billion
≈ $14.48 Million
--

About JW Shinyak Corporation

KQ:067290 Korea Pharmaceuticals
Market Cap
$76.87 Million
₩113.43 Billion KRW
Market Cap Rank
#20286 Global
#1071 in Korea
Share Price
₩2730.00
Change (1 day)
+16.92%
52-Week Range
₩1254.00 - ₩2730.00
All Time High
₩10766.98
About

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more